Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of lactobacillus rhamnosus CCFM1060 in preparation of functional microbial agents, foods and/or medicines

A technology of Lactobacillus rhamnosus and functional bacterial agents, applied in the direction of Lactobacillus, bacteria used in food preparation, applications, etc., can solve the problems of imperfect pathological mechanisms, improve oral glucose tolerance, reduce the area of , reduce the effect of pancreas and liver pathological damage

Pending Publication Date: 2020-01-03
JIANGNAN UNIV
View PDF0 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to its imperfect pathological mechanism, there are no drugs specifically targeting NAFLD on the market, and the treatment can only be improved from diet and lifestyle, supplemented by drugs that lower blood lipids or blood sugar to achieve better results

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lactobacillus rhamnosus CCFM1060 in preparation of functional microbial agents, foods and/or medicines
  • Application of lactobacillus rhamnosus CCFM1060 in preparation of functional microbial agents, foods and/or medicines
  • Application of lactobacillus rhamnosus CCFM1060 in preparation of functional microbial agents, foods and/or medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Example 1: Lactobacillus rhamnosus CCFM1060 has good tolerance to simulated gastrointestinal fluid

[0054] The cryopreserved Lactobacillus rhamnosus CCFM1060 was inoculated into mMRS medium (MRS medium + 0.05% cysteine ​​hydrochloride), cultured anaerobic at 37°C for 48 hours, and then subcultured in mMRS medium for 2~ After 3 times, take 1 mL of Lactobacillus rhamnosus CCFM1060 culture solution, mix with 9.0 mL pH 2.5 artificial gastric juice (mMRS medium containing 1% pepsin, pH=2.5), and culture it anaerobic at 37°C. Samples were taken at 0h, 0.5h, 1h, and 2h, and the plate colonies were counted by pouring and culturing with mMRS agar medium to determine the number of viable bacteria and calculate their survival rate.

[0055] The survival rate is the ratio of the logarithm of the number of viable bacteria in the culture solution at the time of sampling to the logarithm of the number of viable bacteria at the 0 h, expressed in %. Take 1 mL of Lactobacillus rhamnosus CCF...

Embodiment 2

[0060] Example 2: Lactobacillus rhamnosus CCFM1060 has no toxic and side effects on C57BL / 6J mice

[0061] Suspend Lactobacillus rhamnosus CCFM1060 in a 3% sucrose solution to a concentration of 3.0 × 10 9 CFU / mL bacterial suspension. Eight healthy male C57BL / 6J mice weighing about 16-20g were taken, and after one week of adaptation to the environment, the bacteria suspension was administered to the stomach once a day, observed for one week, and recorded death and body weight.

[0062] The results of these tests are listed in Table 3. These results show that the feeding concentration of 3.0×10 9 The CFU / mL Lactobacillus rhamnosus CCFM1060 did not cause significant effects on the mice, there was no significant change in body weight, and no death occurred. The mice have no obvious pathological symptoms.

[0063] Table 3 Changes in body weight and death of mice

[0064]

[0065]

[0066] Note: -: No mice died

Embodiment 3

[0067] Example 3: The effect of Lactobacillus rhamnosus CCFM1060 on the intestinal Desulfovibrio of type 2 diabetic mice:

[0068] Take 40 healthy male C57BL / 6J mice weighing 16-20g, adapt to the environment for 1 week, and randomly divide them into 5 groups: blank control group (NC), model control group (M), rosiglitazone control group (RH) , Lactobacillus rhamnosus CCFM1060 intervention group (CCFM1060), Lactobacillus rhamnosus 4-1 control group (4-1) each group contains 8 mice, and the dose of gavage bacteria suspension is 3.0×10 9 CFU / mL, resuspended in 3% sucrose solution. The experimental animal grouping and treatment methods are shown in Table 4:

[0069] Table 4 Group of experimental animals

[0070]

[0071] Weeks 2-7: The mice in the normal group were fed normal diet, and the remaining mice were fed high-fat diet.

[0072] On the 1st day of the 11th week, all mice were fasted for 12 hours without water, the normal group was injected with 50mmol / L citric acid-sodium citrate ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of lactobacillus rhamnosus CCFM1060 in preparation of functional microbial agents, foods and / or medicines. The lactobacillus rhamnosus CCFM1060 can tolerate thegastrointestinal environment of the human body, significantly improve fasting blood glucose rise and abnormal oral glucose tolerance of type 2 diabetics caused by high fat diet and STZ injection, reduce the area under the curve during glucose tolerance drug administration, and relieve insulin resistance; remarkably improve the increase of total cholesterol content and the increase of low-density lipoprotein cholesterol in serum of type 2 diabetics caused by high-fat diet and STZ injection; obviously relieve the inflammatory state of the liver; and significantly reduce pancreatic and liver pathological injuries caused by high-fat diet and STZ injection. The lactobacillus rhamnosus CCFM1060 has relatively strong adsorption capacity on perfluorooctanoic acid (PFOA), and has the capacity of relieving the toxicity of the PFOA.

Description

Technical field [0001] The invention belongs to the technical field of functional microorganisms, and specifically relates to the application of Lactobacillus rhamnosus CCFM1060 in the preparation of functional bacterial agents, foods and / or medicines. Background technique [0002] Type 2 diabetes is a combination of elevated fasting blood glucose, low high-density lipoprotein cholesterol, elevated triglycerides, and insulin resistance. It is based on a variety of risk factors that are based on abnormal glucose metabolism, lipid metabolism and protein metabolism. , A clinical syndrome that promotes the occurrence and development of various cardiovascular and cerebrovascular diseases such as atherosclerosis. Because type 2 diabetes is a pathological state in which a variety of metabolic components are abnormally aggregated, and its cluster occurrence is related to insulin resistance, it has become a hot spot in the research fields of cardiovascular disease and liver disease. In a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/747A61P1/16A61P3/06A61P1/10A61P1/18A61P3/10A23L33/135
CPCA61K35/747A61P1/16A61P3/06A61P1/10A61P1/18A61P3/10A23L33/135A23V2002/00A23V2400/175A23V2200/32A23V2200/3262A23V2200/328
Inventor 陈卫王刚司倩赵建新张灏
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com